Download
10194_2024_Article_1790.pdf 2,29MB
WeightNameValue
1000 Titel
  • Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry
1000 Autor/in
  1. Hong, Ja Bin |
  2. Israel-Willner, Heike |
  3. Peikert, Andreas |
  4. Schanbacher, Peter |
  5. Tozzi, Viola |
  6. Köchling, Monika |
  7. Reuter, Uwe |
  8. Raffaelli, Bianca |
  9. NTD Study Group |
1000 Verlag Springer Milan
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-06-03
1000 Erschienen in
1000 Quellenangabe
  • 25(1):90
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s10194-024-01790-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11145812/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway have shown good efficacy in migraine prophylaxis. However, a subset of patients does not respond to the first mAb treatment and switches among the available mAbs. The goal of this study is to characterize the switching pattern of migraine patients treated with anti-CGRP(-receptor, -R) mAbs, and to describe the headache burden of those who did not switch, switched once, and switched twice.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>This study used real world data from the NeuroTransData Cohort, a registry of migraine patients treated at outpatient neurology clinics across Germany. Patients who had received at least one anti-CGRP(-R) mAb were included. Headache diaries were collected at baseline and during treatment, along with quality of life measures every three months. Results were summarized for the subgroups of patients who did not switch and those with one and two switches.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>Of the 655 eligible patients, 479 did not switch, 135 switched once, 35 twice, and 6 three or more times. The ≥ 50% response rates for monthly migraine days were 64.7%, 50.7%, and 25.0% for the no switch, one switch, and two switches groups in their last treatment cycles, respectively. Quality of life measures improved for the no switch and one switch groups, but not for the two switches group.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Patients who switched among anti-CGRP(-R) mAbs during the course of their treatment still benefited overall but to a lesser extent than those who did not switch. Treatment response in patients who switched twice was markedly lower compared to the no switch and one switch subgroup.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal Cost of Illness [MeSH]
lokal Antibodies, Monoclonal/therapeutic use [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Monoclonal antibody
lokal Receptors, Calcitonin Gene-Related Peptide/immunology [MeSH]
lokal Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use [MeSH]
lokal Drug Substitution/statistics
lokal Middle Aged [MeSH]
lokal Real-world experience
lokal Receptors, Calcitonin Gene-Related Peptide/metabolism [MeSH]
lokal Calcitonin Gene-Related Peptide Receptor Antagonists/administration
lokal Germany/epidemiology [MeSH]
lokal Calcitonin-gene-related peptide
lokal Male [MeSH]
lokal Prophylaxis
lokal Quality of Life [MeSH]
lokal Research
lokal Calcitonin Gene-Related Peptide/immunology [MeSH]
lokal Migraine Disorders/drug therapy [MeSH]
lokal Migraine
lokal Registries [MeSH]
lokal Migraine Disorders/immunology [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SG9uZywgSmEgQmlu|https://frl.publisso.de/adhoc/uri/SXNyYWVsLVdpbGxuZXIsIEhlaWtl|https://frl.publisso.de/adhoc/uri/UGVpa2VydCwgQW5kcmVhcw==|https://frl.publisso.de/adhoc/uri/U2NoYW5iYWNoZXIsIFBldGVy|https://frl.publisso.de/adhoc/uri/VG96emksIFZpb2xh|https://frl.publisso.de/adhoc/uri/S8O2Y2hsaW5nLCBNb25pa2E=|https://frl.publisso.de/adhoc/uri/UmV1dGVyLCBVd2U=|https://frl.publisso.de/adhoc/uri/UmFmZmFlbGxpLCBCaWFuY2E=|https://frl.publisso.de/adhoc/uri/TlREIFN0dWR5IEdyb3Vw
1000 Hinweis
  • DeepGreen-ID: 9b483630eec5404ba668e82abf5fb9e9 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6518043.rdf
1000 Erstellt am 2025-07-05T08:27:45.562+0200
1000 Erstellt von 322
1000 beschreibt frl:6518043
1000 Zuletzt bearbeitet 2025-08-19T20:01:43.062+0200
1000 Objekt bearb. Tue Aug 19 20:01:43 CEST 2025
1000 Vgl. frl:6518043
1000 Oai Id
  1. oai:frl.publisso.de:frl:6518043 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source